Strategy Is in Vogue from Large Pharma Companies to Biotechs and Foundations Pharmaceutical companies on average spent $1.1 billion to develop and launch a new drug during the late 1990s, according to ...

Unique approach uses Thomson Reuters drug data and expert analysis to identify repositioning candidates PHILADELPHIA, PA, October 23, 2012 – With more than 2,000 drugs reintroduced for alternative ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ -- Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of ...

When it comes to drug repurposing, companies may be searching for a systematic approach to serendipity. The emphasis, however, still seems to be on the serendipity part of the equation. In this regard ...

Astellas has turned to Biovista for help finding new indications for some of its existing compounds. The project is underpinned by Biovista's Clinical Outcome Search Space (COSS) technology, a tool ...